For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

You are here

Publications

Found 8 results
Author Title [ Type(Desc)] Year
Filters: Author is Lu, Min  [Clear All Filters]
Journal Article
Dey AK, David KB, Lu M, Moore JP.  2009.  Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins.. Virology. 385(1):275-81.
Ketas TJ, Schader SM, Zurita J, Teo E, Polonis V, Lu M, Klasse PJohan, Moore JP.  2007.  Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.. Virology. 364(2):431-40.
Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP.  2010.  IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines.. AIDS Res Hum Retroviruses. 26(4):445-58.
Veazey RS, Klasse PJohan, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ et al..  2005.  Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion.. Nature. 438(7064):99-102.
Liu J, Deng Y, Li Q, Dey AK, Moore JP, Lu M.  2010.  Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion.. J Virol. 84(1):201-9.
W Horne S, Johnson LM, Ketas TJ, Klasse PJohan, Lu M, Moore JP, Gellman SH.  2009.  Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers.. Proc Natl Acad Sci U S A. 106(35):14751-6.
Liu J, Deng Y, Dey AK, Moore JP, Lu M.  2009.  Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation.. Biochemistry. 48(13):2915-23.
Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP.  2009.  Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.. PLoS Pathog. 5(8):e1000548.